• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
One of these things is not like the others: the idea of precedence in health technology assessment and coverage decisions.其中有一点与众不同:卫生技术评估和覆盖决策中的优先顺序概念。
Milbank Q. 2005;83(2):193-223. doi: 10.1111/j.1468-0009.2005.00344.x.
2
Confronting the "gray zones" of technology assessment: evaluating genetic testing services for public insurance coverage in Canada.直面技术评估的“灰色地带”:评估加拿大公共保险覆盖范围内的基因检测服务
Int J Technol Assess Health Care. 2003 Spring;19(2):301-16. doi: 10.1017/s0266462303000278.
3
Early assessment of medical technologies to inform product development and market access: a review of methods and applications.早期评估医疗技术以支持产品开发和市场准入:方法和应用综述。
Appl Health Econ Health Policy. 2011 Sep 1;9(5):331-47. doi: 10.2165/11593380-000000000-00000.
4
Reflections on science, judgment, and value in evidence-based decision making: a conversation with David Eddy by Sean R. Tunis.循证决策中的科学、判断与价值之思考:肖恩·R·图尼斯与大卫·埃迪的对话
Health Aff (Millwood). 2007 Jul-Aug;26(4):w500-15. doi: 10.1377/hlthaff.26.4.w500. Epub 2007 Jun 19.
5
Key principles for the improved conduct of health technology assessments for resource allocation decisions.用于资源分配决策的卫生技术评估改进实施的关键原则。
Int J Technol Assess Health Care. 2008 Summer;24(3):244-58; discussion 362-8. doi: 10.1017/S0266462308080343.
6
Risk management frameworks for human health and environmental risks.人类健康与环境风险的风险管理框架。
J Toxicol Environ Health B Crit Rev. 2003 Nov-Dec;6(6):569-720. doi: 10.1080/10937400390208608.
7
An economic theory of the fourth hurdle.第四道门槛的经济理论。
Health Econ. 2013 May;22(5):600-10. doi: 10.1002/hec.2830. Epub 2012 Apr 30.
8
Role of technology assessment in health benefits coverage for medical devices.技术评估在医疗设备健康效益覆盖中的作用。
Am J Manag Care. 1998 Sep 25;4 Spec No:SP139-50.
9
Cost-effectiveness analysis and formulary decision making in England: findings from research.英国的成本效益分析与处方集决策制定:研究结果
Soc Sci Med. 2007 Nov;65(10):2116-29. doi: 10.1016/j.socscimed.2007.06.009. Epub 2007 Aug 14.
10
The role of health technology assessment in coverage decisions on newborn screening.健康技术评估在新生儿筛查覆盖决策中的作用。
Int J Technol Assess Health Care. 2011 Oct;27(4):313-21. doi: 10.1017/S0266462311000468.

引用本文的文献

1
Towards an Explanation of the Social Value of Health Systems: An Interpretive Synthesis.迈向健康系统社会价值解释之路:阐释性综合研究。
Int J Health Policy Manag. 2021 Jul 1;10(7):414-429. doi: 10.34172/ijhpm.2020.159.
2
Understanding relevance of health research: considerations in the context of research impact assessment.理解健康研究的相关性:研究影响评估背景下的考量因素
Health Res Policy Syst. 2017 Apr 17;15(1):31. doi: 10.1186/s12961-017-0188-6.
3
Steps toward improving ethical evaluation in health technology assessment: a proposed framework.改善卫生技术评估中伦理评估的步骤:一个提议的框架。
BMC Med Ethics. 2016 Jun 6;17(1):34. doi: 10.1186/s12910-016-0118-0.
4
Why not integrate ethics in HTA: identification and assessment of the reasons.为何不将伦理纳入卫生技术评估:原因的识别与评估
GMS Health Technol Assess. 2014 Nov 26;10:Doc04. doi: 10.3205/hta000120. eCollection 2014.
5
Analysing coverage decision-making: opening Pandora's box?分析医保覆盖范围决策:打开潘多拉魔盒?
Eur J Health Econ. 2014 Dec;15(9):899-906. doi: 10.1007/s10198-014-0566-8. Epub 2014 Feb 6.
6
The force of dissimilar analogies in bioethics.生物伦理学中不同类比的力量。
Theor Med Bioeth. 2011 Apr;32(2):117-28. doi: 10.1007/s11017-010-9165-6.
7
6-STEPPPs: A Modular Tool to Facilitate Clinician Participation in Fair Decisions for Funding New Cancer Drugs.6-STEPPPs:一个用于促进临床医生参与公平决策以资助新型癌症药物的模块化工具。
J Oncol Pract. 2008 Jan;4(1):2-7. doi: 10.1200/JOP.0812001.
8
Combining multicriteria decision analysis, ethics and health technology assessment: applying the EVIDEM decision-making framework to growth hormone for Turner syndrome patients.结合多准则决策分析、伦理学和卫生技术评估:将 EVIDEM 决策框架应用于特纳综合征患者的生长激素治疗。
Cost Eff Resour Alloc. 2010 Apr 8;8:4. doi: 10.1186/1478-7547-8-4.
9
Technology assessment and resource allocation for predictive genetic testing: a study of the perspectives of Canadian genetic health care providers.预测性基因检测的技术评估与资源分配:加拿大基因医疗服务提供者观点研究
BMC Med Ethics. 2009 Jun 18;10:6. doi: 10.1186/1472-6939-10-6.
10
How good is good enough? Standards in policy decisions to cover new health technologies.怎样才算足够好?新卫生技术纳入政策决策的标准。
Healthc Policy. 2007 Nov;3(2):91-101.

本文引用的文献

1
Confronting the "gray zones" of technology assessment: evaluating genetic testing services for public insurance coverage in Canada.直面技术评估的“灰色地带”:评估加拿大公共保险覆盖范围内的基因检测服务
Int J Technol Assess Health Care. 2003 Spring;19(2):301-16. doi: 10.1017/s0266462303000278.
2
Viagra and contraceptives.伟哥与避孕药。
Health Aff (Millwood). 2003 Jan-Feb;22(1):277. doi: 10.1377/hlthaff.22.1.277.
3
An ethical template for pharmacy benefits.药房福利的道德模板。
Health Aff (Millwood). 2003 Jan-Feb;22(1):125-37. doi: 10.1377/hlthaff.22.1.125.
4
Theory skepticism and moral dilemmas.理论怀疑主义与道德困境
Kennedy Inst Ethics J. 2002 Sep;12(3):279-98. doi: 10.1353/ken.2002.0020.
5
Lifestyle drug market booming.生活方式类药物市场蓬勃发展。
Nat Med. 2002 Sep;8(9):909. doi: 10.1038/nm0902-909.
6
Will genetic testing alter the management of disease caused by infectious agents? A cost-effectiveness analysis of gene-testing strategies for prevention of rheumatic Fever.基因检测会改变由感染因子引起的疾病的治疗方式吗?一项关于预防风湿热的基因检测策略的成本效益分析。
Clin Infect Dis. 2002 Jun 1;34(11):1491-9. doi: 10.1086/340341.
7
Limits to health care: fair procedures, democratic deliberation, and the legitimacy problem for insurers.医疗保健的局限:公平程序、民主审议与保险公司的正当性问题
Philos Public Aff. 1997 Fall;26(4):303-50. doi: 10.1111/j.1088-4963.1997.tb00082.x.
8
Casuistry: an alternative or complement to principles?决疑法:原则的替代方案还是补充?
Kennedy Inst Ethics J. 1995 Sep;5(3):237-51. doi: 10.1353/ken.0.0016.
9
Interactive technology assessment and wide reflective equilibrium.交互式技术评估与广泛的反思平衡。
J Med Philos. 2001 Jun;26(3):245-61. doi: 10.1076/jmep.26.3.245.3015.
10
Reducing normative bias in health technology assessment: interactive evaluation and casuistry.减少卫生技术评估中的规范偏差:交互式评估与决疑法
Med Health Care Philos. 1999;2(3):255-63. doi: 10.1023/a:1009963018813.

其中有一点与众不同:卫生技术评估和覆盖决策中的优先顺序概念。

One of these things is not like the others: the idea of precedence in health technology assessment and coverage decisions.

作者信息

Giacomini Mita

机构信息

Centre for Health Economics and Policy Analysis, Department of Clinical Epidemiology and Biostatistics, McMaster University, 1200 Main Street West, HSC-3H1C, Hamilton, Ontario L8N 3Z5, Canada.

出版信息

Milbank Q. 2005;83(2):193-223. doi: 10.1111/j.1468-0009.2005.00344.x.

DOI:10.1111/j.1468-0009.2005.00344.x
PMID:15960769
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2690141/
Abstract

Health plans often deliberate covering technologies with challenging purposes, effects, or costs. They must integrate quantitative evidence (e.g., how well a technology works) with qualitative, normative assessments (e.g., whether it works well enough for a worthwhile purpose). Arguments from analogy and precedent help integrate these criteria and establish standards for their policy application. Examples of arguments are described for three technologies (ICSI, genetic tests, and Viagra). Drawing lessons from law, ethics, philosophy, and the social sciences, a framework is developed for case-based evaluation of new technologies. The decision-making cycle includes (1) taking stock of past decisions and formulating precedents, (2) deciding new cases, and (3) assimilating decisions into the case history and evaluation framework. Each stage requires distinctive decision maker roles, information, and methods.

摘要

医疗保健计划常常会慎重考虑是否涵盖那些目标、效果或成本具有挑战性的技术。它们必须将定量证据(例如,一项技术的效果如何)与定性的、规范性评估(例如,它是否足以实现有价值的目标)相结合。类比论证和先例论证有助于整合这些标准,并为其政策应用确立标准。文中描述了针对三种技术(胞浆内单精子注射、基因检测和伟哥)的论证示例。借鉴法律、伦理、哲学和社会科学的经验,开发了一个基于案例的新技术评估框架。决策周期包括:(1)总结过去的决策并制定先例;(2)裁决新的案例;(3)将决策纳入案例历史和评估框架。每个阶段都需要不同的决策者角色、信息和方法。